Component

Human narcolepsy-associated excessive sleepiness

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Forty-week open-label narcolepsy extensions reported sustained benefit without observed tolerance during that period, with completer selection and later attrition.

    Experimental context and source evidence
    evidence_access
    Primary indexed abstract checked; full methods and figures not comprehensively reviewed.
    experimental_contrast
    {"intervention": "Continued modafinil in trial completers", "comparator": "Within-study baseline/follow-up", "endpoint": "Forty-week open-label narcolepsy extensions reported sustained benefit without observed tolerance during that period, with completer selection and later attrition.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Human open-label extension studies, forty weeks; no proof that tolerance never occurs.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    Forty-week open-label narcolepsy extensions reported sustained benefit without observed tolerance during that period, with completer selection and later attrition.
    primary_references
    Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. | 2000 | DOI 10.1016/s1389-9457(00)00031-9 | PMID 10828434 | https://pubmed.ncbi.nlm.nih.gov/10828434/
    source_locator
    Reviewed reference lines 164-164; exact primary location described in quoted passage where extracted.

    Modafinil: detailed mechanisms of action (reviewed 3 October 2026) · lines 164–164

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human open-label extension studies, forty weeks; no proof that tolerance never occurs. · Recorded from source · Recorded from source

    Reinforcement, tolerance and withdrawal are different endpoints. Forty-week open-label narcolepsy extensions reported sustained benefit without evidence of tolerance during that period, but enrolled completers of prior trials and had subsequent attrition. They cannot demonstrate that tolerance never occurs over years or that all exposure patterns have the same discontinuation effects. [Long-term extension studies](https://pubmed.ncbi.nlm.nih.gov/10828434/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.